Nevertheless, combination immunotherapy strategies such as the addition of CTLA-4 inhibitors that utilize additional anti-immunity pathways without solely depending on T-cell mediated anti-tumor immunity, and mechanisms that restore antigen presentation by inhibiting TGFß signaling, may improve the outcomes of patients with metastatic melanoma who are progressing on PD-1 inhibitors. Here, PDCD1 is linked to neoplasm.